Articles Archives - Page 239 of 733

WednesdaySep 21, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Provide Bioavailable Oral Treatment for Hypertension, Mitigate Effects of High Blood Pressure

Lexaria is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) The company has developed the patented DehydraTECH(TM) drug delivery technology, which has been shown to deliver more API at a faster rate than controls Lexaria’s DehydraTECH pipeline includes DehydraTECH-CBD for the treatment of hypertension Through pre-clinical studies, DehydraTECH-CBD has been shown to decrease systolic blood pressure among hypertensive volunteers The company intends to file an Investigational New Drug (“IND”) application and has already received confirmation that the FDA agrees with its proposed abbreviated pathway under section 501(b)(2) Oral…

TuesdaySep 20, 2022 1:30 pm

Freight Technologies Inc. (NASDAQ: FRGT) Using Technology to Help Customers Overcome Challenges of Cross-Border Logistics, Greatly Improving Efficiency

Freight Technologies is a technology company that develops solutions aimed at optimizing and automating the supply chain process The company’s solutions include Fr8App Platform, Fr8FMS, cloud-based Fr8TMS, Fr8Radar, Fr8Data, and Fr8Fleet Early this year, Freight Technologies unveiled Fr8Fleet, a technology solution for committed capacity planning, and announced it had secured its first contract for this product with Kimberly Clark de Mexico (“KCM”) The company recently reported an expanded relationship with KCM following an agreement to include the Fr8App platform for cross-border logistics for shipments from Mexico to the U.S. An insights report by multinational KPMG, entitled “The challenges of cross-border…

TuesdaySep 20, 2022 12:45 pm

Flora Growth Corp. (NASDAQ: FLGC) Agreement with Colombian Tribe Strengthens Cannabis Production Supply Chain

Flora Growth is a global cannabis brand-builder focused on the cultivation of product at a central Colombian facility and marketing through a design-led international supply chain Flora recently announced an agreement with Colombia’s Misak tribe for cooperative processing and distribution of cannabis, drawing on the tribe’s licensing advantage to accelerate the pair’s marketing capacity Flora is headquartered in Canada, but its strength lies in its Colombian-based cultivation operations centered in Colombia, one of the largest licensed outdoor operations in the world In recent years, Colombia’s government has been working to create a legalization framework for cannabis cultivation, processing and exportation…

TuesdaySep 20, 2022 12:00 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

First dose is administered as first-ever novel psilocybin analog enters clinical development Cybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybin The high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective therapeutics. The company is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. Late last month, the first two trial participants…

TuesdaySep 20, 2022 11:15 am

QSAM Biosciences Inc. (QSAM) Working to Halt, Regress Bone Tumors in Children Through Therapeutic Radiopharmaceuticals

Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organization QSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient populations Company creating pipeline of novel radiotherapeutics to serve multiple indications with its lead product, CycloSam With the overall incidence of childhood cancer on the rise, the work of QSAM Biosciences (OTCQB: QSAM) is becoming increasingly important. QSAM Biosciences is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric…

TuesdaySep 20, 2022 10:30 am

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Expands Canadian RNG Projects, Achieves Key Milestones

Traditional natural gas extraction pollutes air, contaminates water, disturbs landscape Renewable natural gas is derived from organic sources, compatible with existing traditional natural gas pipeline grid EverGen operates projects in British Columbia and Alberta, recently acquired 50 percent stake in Ontario-based Project Radius located in Eastern Canada Company recently signed $31 million senior term loan to help fund RNG facility upgrades and expand projects Traditional pipeline natural gas is extracted by vertical or horizontal drilling, and hydraulic fracturing. Well-drilling activities pollute the air, disturb lands, and contaminate water, while hydraulic fracturing - widely referred to as “fracking” - has similar…

TuesdaySep 20, 2022 9:45 am

Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Ranked in Top 10 of Cybersecurity Startups

The UK's fastest-growing platform for startups, TechRound, named Cerberus in the top 10 cybersecurity startups and companies Cerberus Sentinel is a nationwide provider of cybersecurity consulting and managed services, with offices and resources across the country Company believes culture is the foundation of every successful cybersecurity and compliance program Cerberus Cyber Sentinel (NASDAQ: CISO) was named in the top 10 cybersecurity startups and companies by TechRound, the voice of UK startups and the UK's fastest-growing platform for startups (https://ibn.fm/cHuEr). Chosen by TechRound’s internal team, the companies were ranked based on “the experience of the team, founders and staff; how the…

TuesdaySep 20, 2022 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere In September 2022, the company announced it was granted a patent for its 12-lead ECG Patch Monitor, opening a pathway to ischemia and arrhythmia detection innovation in ECG Patch products In August 2022, the company announced it was seeking FDA approval for its HeartBeam AIMI platform technology used to detect and diagnose heart attacks On November 15, 2021, HeartBeam had its IPO on the Nasdaq under ticker symbol ‘BEAT’ The company’s management team has significant experience in software…

MondaySep 19, 2022 12:45 pm

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA) Works Towards Potential Breakthrough Solution for Electric Vehicle and Clean Energy Industries

Power electronics, especially those found in the traction inverters used in EVs, are key to achieving better range, safety, and lifetime; still, improving inverter efficiency has been relatively slow Hillcrest stepped up to the challenge of developing a high-efficiency inverter — a new class of clean technology designed to help today’s electric power systems overcome their common limitations Hillcrest’s unique inverter architecture can be deployed across different applications, providing opportunities for diversification and de-risking of the company's revenue streams Although the popularity of electric vehicles continues to grow amid the ongoing push for energy transition, their design challenges, such as…

MondaySep 19, 2022 12:00 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment

Glioblastoma multiforme (“GBM”) is one of the most aggressive, deadly, and treatment-resistant forms of cancer within the brain, with an average life expectancy of 12-18 months and more than 50,000 new cases each year The current standard of care for GBM is ineffective for approximately 60% of patients Initial Phase 1 trial information for Berubicin (approximately 14 years ago) resulted in one patient surviving cancer-free to present and two experiencing significant tumor reduction of up to 80% CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, recently participated in the…

Site Search

Company Search

Category: Articles